Healthcare Industry News: hematology analyzer
News Release - April 16, 2007
Abbott and Premier Sign Contract for Diagnostic TestsABBOTT PARK, Ill., April 16 (HSMN NewsFeed) -- Abbott (NYSE: ABT ) announced today that it has signed a new group purchasing agreement with Premier, Inc., a leading healthcare alliance, for a broad line of the company's diagnostic products.
The three-year contract covers all of Abbott's immunochemistry analyzers, reagents and accessories, as well as all CELL-DYNŽ hematology analyzers, products and service.
Abbott also will work with Premier, Inc. to help with laboratory automation, which will help member hospitals deliver quality lab results while maximizing resources.
The contract represents potential sales to Premier members in excess of $300 million over three years.
"Our products have proven themselves in enhancing the productivity of high volume labs," said Scott Luse, divisional vice president, Marketing, Abbott Diagnostics. "We look forward to partnering with Premier to help its member hospitals improve operating efficiencies and patient care."
About Premier, 2006 Malcolm Baldrige National Quality Award recipient
Serving 1,700 hospitals and more than 44,000 other healthcare sites, Premier Inc. is the largest healthcare alliance in the United States dedicated to improving patient outcomes while safely reducing the cost of care. Owned by not-for-profit hospitals, Premier operates the nation's largest healthcare purchasing network, the most comprehensive repository of hospital clinical and financial information and one of the largest policy-holder owned, hospital professional liability risk-retention groups in healthcare. Headquartered in San Diego, Premier has offices in Charlotte, N.C. and Washington. For more information, visit http://www.premierinc.com.
About Abbott Diagnostics
Abbott Diagnostics is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, blood banks, physician offices and clinics. With more than 69,000 institutional customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, cost effectiveness and flexibility. Abbott has helped transform the practice of medical diagnostics from an art to a science through the company's commitment to improving patient care and lowering overall costs. The history of Abbott Diagnostics is filled with examples of first-of-a-kind products and significant technological advancements.
On Jan. 18, 2007, Abbott announced that it will sell its core laboratory diagnostics business, including the Abbott Diagnostics Division and Abbott Point of Care, to GE for $8.13 billion in cash. The sale is subject to customary closing conditions, including regulatory approvals.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAbbott Expands Peripheral Vascular Offerings with Acquisition of Walk Vascular, LLC
Abbott's Amplatzer(TM) Amulet(TM) Device Approved by FDA to Treat People With Atrial Fibrillation at Risk of Stroke
Abbott's FreeStyle(R) Libre 2 iOS App Cleared in U.S., Providing a Seamless Digital Experience to Simplify Diabetes Management